Vietnam Ministry of Health Includes Still Investigational Molnupiravir on National COVID-19 Treatment Protocol

According to Vietnamese media, the Vietnamese health ministry added 400 mg Molnupiravir to its COVID-19 treatment protocol, which also includes Favipiravir and Remdesivir. TrialSite reported that in Ho Chi Minh City, the department of health has conducted an unorthodox home care pilot, including the experimental antiviral drug still under investigation. The pilot care program targets COVID-19 patients with mild symptoms aged 18 to 65 with no signs of pneumonia or oxygen shortage for a five-day regimen. TrialSite reported on this program, including an interview with a participant.  But the home care program involving the Merck drug was part of a local municipal effort. However, based on a recent media entry, the Vietnam Ministry of Health at the national level includes the still-experimental drug as part of its national treatment protocol. Is Molnupiravir on an even faster track in Vietnam than in the lucrative American market?

TrialSite wasn’t able to verify yet with the Vietnam Ministry of Health as to the veracity of the Vietnam Net piece, however, the timing coincides with Merck’s recent report that due to positive data, a large study’s independent safety data monitoring com...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee